IPSEN, OOO
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 1929-01-01
- Employees
- 5.7K
- Market Cap
- $9.8B
- Website
- https://www.ipsen.com/
Study to Predict Lanreotide-induced Disease Activity Normalization in Acromegaly
- Conditions
- Acromegaly
- First Posted Date
- 2019-07-01
- Last Posted Date
- 2020-06-02
- Lead Sponsor
- Ipsen
- Registration Number
- NCT04003519
Spasticity and Treatment Satisfaction Among Stroke Survivors
- Conditions
- Spasticity as Sequela of Stroke
- First Posted Date
- 2019-06-24
- Last Posted Date
- 2020-06-01
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 30
- Registration Number
- NCT03995524
- Locations
- 🇫🇷
Ipsen Central Contact, Paris, France
Lanreotide 120mg Effectiveness in Subjects With Pancreatic Neuroendocrine Tumours (PanNET) in Routine Clinical Practice.
- Conditions
- Pancreatic Neuroendocrine Tumor
- First Posted Date
- 2019-05-13
- Last Posted Date
- 2021-06-14
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 54
- Registration Number
- NCT03947762
- Locations
- 🇪🇸
Hospital Basurto, Bilbao, Spain
🇪🇸Hospital General Ciudad Real, Ciudad Real, Spain
🇪🇸Hospital Torrecardenas, Almería, Spain
Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors
- Conditions
- Locally Advanced or Metastatic Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2019-05-10
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 127
- Registration Number
- NCT03945773
- Locations
- 🇳🇱
Maxima Medisch Centrum, Eindhoven, Netherlands
🇨🇭Kantonsspital St. Gallen, Saint Gallen, Switzerland
🇬🇧The Christie NHS Foundation Trust, Manchester, United Kingdom
Study to Assess the Use of Lanreotide Autogel® 120 mg in Patients With Locally Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) in Routine Clinical Practice
- Conditions
- Neuroendocrine Tumors
- First Posted Date
- 2019-03-29
- Last Posted Date
- 2020-11-05
- Lead Sponsor
- Ipsen
- Registration Number
- NCT03895463
- Locations
- 🇵🇱
Uniwersyteckie Centrum Kliniczne im. Prof. K. Gibińskiego Śląskiego Uniwersytetu Medycznego w Katowicach, Katowice, Poland
🇵🇱Uniwersyteckie Centrum Kliniczne, Gdańsk, Poland
🇵🇱Samodzielny Publiczny Szpital Kliniczny Nr 1 Pomorskiego Uniwersytetu Medycznego im. prof. Tadeusza Sokołowskiego, Szczecin, Poland
Dose Escalation and Dose Expansion Study of IPN60090 in Patients With Advanced Solid Tumours
- Conditions
- Solid Tumor
- Interventions
- First Posted Date
- 2019-03-28
- Last Posted Date
- 2022-09-13
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 22
- Registration Number
- NCT03894540
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Validation of Patient Reported Outcome Measures for Use in Hallux Valgus
- Conditions
- Hallux Valgus
- First Posted Date
- 2019-02-20
- Last Posted Date
- 2020-01-27
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 21
- Registration Number
- NCT03846687
- Locations
- 🇺🇸
Futuro Clinical Trials, LLC, McAllen, Texas, United States
🇺🇸Ankle and Foot Care Centers, Youngstown, Ohio, United States
🇺🇸University Foot and Ankle Institute, Santa Monica, California, United States
Post-marketing Surveillance on the Safety of CabometyxTM in Korean Patients
- Conditions
- Hepatocellular CarcinomaDifferentiated Thyroid CarcinomaRenal Cell Carcinoma
- First Posted Date
- 2018-12-14
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 347
- Registration Number
- NCT03776123
- Locations
- 🇰🇷
Asan Medical Center (Site B), Seoul, Korea, Republic of
🇰🇷Kyungpook National University Chilgok Hospital, Daegu, Korea, Republic of
🇰🇷Kosin University Gospel Hospital (Site B), Pusan, Korea, Republic of
Evaluate the Safety, Tolerability, Biodistribution and Anti Tumour Activity of 177LU-OPS201 With Companion Imaging 68Ga-OPS202 PET/CT in Previously Treated Subjects With Locally Advanced or Metastatic Cancers Expressing Somatostatin Receptor 2 (SSTR2)
- Conditions
- Small Cell Lung Cancer and Breast Cancer
- Interventions
- First Posted Date
- 2018-12-12
- Last Posted Date
- 2022-09-13
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 9
- Registration Number
- NCT03773133
- Locations
- 🇫🇷
CHU de Marseille - Hôpital la Timone, Marseille, France
🇩🇪Universitaetsklinikum Essen, Essen, Germany
🇨🇭University Hospital Basel, Basel, Switzerland
Validation of Patient Reported Outcome Measures for Use in Vulvodynia
- Conditions
- Vulvodynia
- First Posted Date
- 2018-12-10
- Last Posted Date
- 2019-10-28
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 20
- Registration Number
- NCT03770169
- Locations
- 🇺🇸
San Diego Sexual Medicine, San Diego, California, United States
🇺🇸Center for Vulvovaginal Disorders, Washington, District of Columbia, United States
🇺🇸Omaha OB-GYN Associates, PC, Omaha, Nebraska, United States